REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced a new exclusive, worldwide license agreement, extending the companies’ existing gene therapy partnership. Under the terms of the agreement, REGENXBIO has granted Ultragenyx an exclusive, worldwide license, with rights to sublicense, to REGENXBIO’s NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder.

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it will present and hold a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020, at 2:35 p.m. ET. The conference will be held in a virtual meeting format.

Q4 2019 Regenxbio Inc Earnings Call

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Thursday, May 7, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2020, and recent operational highlights.

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that three oral presentations, and several poster presentations, will be presented at the American Society of Gene and Cell Therapy's 23rd Annual Meeting taking place May 12-15, 2020 in virtual format. Presentations and posters will be available at www.asgct.org.

Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020

RGX-314 continues to be well-tolerated at all dose levels

By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at...

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The growing spread of the coronavirus last week sent the U.S. stock market to its steepest plunge since the 2008 financial crisis, and Greater Washington companies felt the pinch. The Dow suffered a 12.

Q1 2020 Regenxbio Inc Earnings Call

Regenxbio (RGNX) delivered earnings and revenue surprises of -80.00% and -70.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]

Ken Mills became the CEO of REGENXBIO Inc. (NASDAQ:RGNX) in 2009. This analysis aims first to contrast CEO...

More than 4.4 million Americans filed initial unemployment claims for the week ending April 18, bringing the five-week total to about 26.5 million. Continuing unemployment claims are close to 16 million, according to data released Thursday by the Department of Labor. D.C., Maryland and Virginia saw employment claims drop compared with the previous week, but a total of nearly 140,000 residents in the three jurisdictions applied initial claims last week.

The Dow Jones Industrial Average had its worst day since 1987 on Thursday, falling more than 10% as the country dealt with the spread of the novel coronavirus and its uncertain impacts on business. The S&P 500 and the Nasdaq were close behind, each falling more than 9%.

Last week, you might have seen that REGENXBIO Inc. (NASDAQ:RGNX) released its first-quarter result to the market. The...

The spread of the coronavirus beyond China and into Italy, South Korea and Iran caused markets to drop sharply Monday, and some of Greater Washington’s largest public companies were hit by the sell-off.

The Gaithersburg company, which a month ago set out to develop a vaccine for the COVID-19 coronavirus, hopes to win approval to move toward human trials.